Symbols / SSKN Stock $0.19 -2.63% STRATA Skin Sciences, Inc.
SSKN (Stock) Chart
About
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, and other skin conditions; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 1.09M |
| Enterprise Value | 9.47M | Income | -6.26M | Sales | 30.70M |
| Book/sh | 0.49 | Cash/sh | 1.34 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.14 | PEG | — |
| P/S | 0.04 | P/B | 0.37 | P/C | — |
| EV/EBITDA | -5.53 | EV/Sales | 0.31 | Quick Ratio | 0.45 |
| Current Ratio | 0.58 | Debt/Eq | 559.42 | LT Debt/Eq | — |
| EPS (ttm) | -1.35 | EPS next Y | -1.29 | EPS Growth | — |
| Revenue Growth | -3.00% | Earnings | 2026-05-13 | ROA | -11.14% |
| ROE | -158.91% | ROIC | — | Gross Margin | 58.25% |
| Oper. Margin | 0.40% | Profit Margin | -20.40% | Shs Outstand | 5.89M |
| Shs Float | 3.25M | Short Float | 8.13% | Short Ratio | 5.32 |
| Short Interest | — | 52W High | 3.86 | 52W Low | 0.12 |
| Beta | 0.34 | Avg Volume | 443.68K | Volume | 4.89K |
| Target Price | — | Recom | None | Prev Close | $0.19 |
| Price | $0.18 | Change | -2.63% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-02-27 | init | Maxim Group | — → Buy | $6 |
| 2023-05-16 | reit | CG Capital | — → Outperform | $4 |
| 2020-11-03 | up | HC Wainwright & Co. | Neutral → Buy | $3 |
| 2020-03-17 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2019-12-09 | init | Ladenburg Thalmann | — → Buy | $5 |
| 2019-11-21 | init | Oppenheimer | — → Outperform | $7 |
| 2018-12-10 | init | Northland Capital Markets | — → Outperform | $7 |
- SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy - Yahoo Finance Wed, 18 Feb 2026 08
- If You Invested $1,000 in Strata Skin Sciences Inc (SSKN) - Stock Titan Sun, 22 Mar 2026 08
- Can Strata Skin Sciences Stock Recover If Markets Fall? - Trefis ue, 23 Dec 2025 08
- STRATA Skin Sciences stock plunges after Nasdaq delisting notice - investing.com hu, 12 Feb 2026 08
- Should I buy Strata Skin Sciences (SSKN) - Zacks Investment Research Wed, 18 Feb 2026 08
- STRATA Skin Sciences Received Notice of Delisting - TradingView Wed, 11 Feb 2026 08
- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Surges 36% Yet Its Low P/S Is No Reason For Excitement - simplywall.st Sat, 18 Oct 2025 07
- SSKN Stock Explodes Higher on Exciting Breakthrough in Rare Skin Cancer Treatment - RagingBull ue, 14 Oct 2025 07
- Strata Skin Sciences to Delist and Go Dark - TipRanks Wed, 11 Feb 2026 08
- Morning Market Movers: SLE, GLTO, SSKN, IPDN See Big Swings - RTTNews ue, 23 Sep 2025 07
- STRATA Skin Sciences Confirms Nasdaq Delisting - GlobeNewswire hu, 19 Feb 2026 08
- Strata Skin Sciences (NASDAQ: SSKN) plans Nasdaq exit and goes dark - Stock Titan Wed, 11 Feb 2026 08
- STRATA Skin Sciences’ Latest Innovations: Buy or Wait? - StocksToTrade ue, 23 Sep 2025 07
- Analysts Just Made A Major Revision To Their STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Revenue Forecasts - Yahoo Finance Sat, 16 Aug 2025 07
- STRATA Skin Sciences Highlights Meta-Analysis Confirming - GlobeNewswire ue, 17 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
30.70
-8.54%
|
33.56
+0.61%
|
33.36
-7.75%
|
36.16
|
| Operating Revenue |
|
30.70
-8.54%
|
33.56
+0.61%
|
33.36
-7.75%
|
36.16
|
| Cost Of Revenue |
|
12.81
-10.63%
|
14.34
-3.74%
|
14.90
+3.50%
|
14.39
|
| Reconciled Cost Of Revenue |
|
12.81
-10.63%
|
14.34
-3.74%
|
14.90
+3.50%
|
14.39
|
| Gross Profit |
|
17.88
-6.98%
|
19.22
+4.12%
|
18.46
-15.19%
|
21.77
|
| Operating Expense |
|
23.72
-2.04%
|
24.21
-2.31%
|
24.78
-6.19%
|
26.42
|
| Research And Development |
|
0.42
-52.32%
|
0.88
-32.95%
|
1.32
+27.99%
|
1.03
|
| Selling General And Administration |
|
23.30
-0.13%
|
23.33
-0.59%
|
23.46
-7.58%
|
25.39
|
| Selling And Marketing Expense |
|
13.11
+5.48%
|
12.43
-4.06%
|
12.96
-15.33%
|
15.30
|
| General And Administrative Expense |
|
10.18
-6.53%
|
10.90
+3.69%
|
10.51
+4.17%
|
10.09
|
| Other Gand A |
|
10.18
-6.53%
|
10.90
+3.69%
|
10.51
+4.17%
|
10.09
|
| Total Expenses |
|
36.53
-5.23%
|
38.55
-2.85%
|
39.68
-2.77%
|
40.81
|
| Operating Income |
|
-5.83
-17.00%
|
-4.99
+21.09%
|
-6.32
-35.94%
|
-4.65
|
| Total Operating Income As Reported |
|
—
|
-9.26
-7.57%
|
-8.60
-85.07%
|
-4.65
|
| EBITDA |
|
0.18
+106.23%
|
-2.84
+15.92%
|
-3.38
-399.65%
|
1.13
|
| Normalized EBITDA |
|
-0.96
-167.18%
|
1.43
+862.57%
|
-0.19
-116.58%
|
1.13
|
| Reconciled Depreciation |
|
4.47
-15.83%
|
5.31
-10.08%
|
5.90
+3.76%
|
5.69
|
| EBIT |
|
-4.29
+47.36%
|
-8.15
+12.21%
|
-9.28
-103.55%
|
-4.56
|
| Total Unusual Items |
|
1.14
+126.59%
|
-4.27
-33.67%
|
-3.19
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
1.14
+126.59%
|
-4.27
-33.67%
|
-3.19
|
0.00
|
| Special Income Charges |
|
1.14
+126.59%
|
-4.27
-33.67%
|
-3.19
|
0.00
|
| Other Special Charges |
|
-1.14
|
—
|
0.91
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
4.27
+86.87%
|
2.28
|
0.00
|
| Net Income |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Pretax Income |
|
-6.25
+39.07%
|
-10.26
+6.10%
|
-10.92
-99.09%
|
-5.49
|
| Net Non Operating Interest Income Expense |
|
-1.55
+16.94%
|
-1.86
-32.36%
|
-1.41
-68.34%
|
-0.84
|
| Interest Expense Non Operating |
|
1.96
-7.02%
|
2.11
+28.48%
|
1.64
+77.11%
|
0.93
|
| Net Interest Income |
|
-1.55
+16.94%
|
-1.86
-32.36%
|
-1.41
-68.34%
|
-0.84
|
| Interest Expense |
|
1.96
-7.02%
|
2.11
+28.48%
|
1.64
+77.11%
|
0.93
|
| Interest Income Non Operating |
|
0.41
+69.42%
|
0.24
+4.76%
|
0.23
+159.55%
|
0.09
|
| Interest Income |
|
0.41
+69.42%
|
0.24
+4.76%
|
0.23
+159.55%
|
0.09
|
| Other Income Expense |
|
1.14
+133.34%
|
-3.40
-6.61%
|
-3.19
|
—
|
| Other Non Operating Income Expenses |
|
—
|
0.86
|
—
|
—
|
| Tax Provision |
|
0.01
+107.06%
|
-0.17
-84.78%
|
-0.09
-246.03%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
+1166.89%
|
0.00
+96.79%
|
0.00
-95.99%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.24
+436.91%
|
-0.07
-163.03%
|
-0.03
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Net Income From Continuing And Discontinued Operation |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Net Income Continuous Operations |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Normalized Income |
|
-7.16
-21.55%
|
-5.89
+23.16%
|
-7.66
-38.11%
|
-5.55
|
| Net Income Common Stockholders |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Diluted EPS |
|
—
|
-2.65
+14.52%
|
-3.10
-93.75%
|
-1.60
|
| Basic EPS |
|
—
|
-2.65
+14.52%
|
-3.10
-93.75%
|
-1.60
|
| Basic Average Shares |
|
—
|
3.81
+9.03%
|
3.49
+0.60%
|
3.47
|
| Diluted Average Shares |
|
—
|
3.81
+9.03%
|
3.49
+0.60%
|
3.47
|
| Diluted NI Availto Com Stockholders |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
42.02
|
| Current Assets |
|
15.54
|
| Cash Cash Equivalents And Short Term Investments |
|
6.78
|
| Cash And Cash Equivalents |
|
6.78
|
| Receivables |
|
4.44
|
| Accounts Receivable |
|
4.44
|
| Gross Accounts Receivable |
|
4.66
|
| Allowance For Doubtful Accounts Receivable |
|
-0.22
|
| Inventory |
|
2.67
|
| Raw Materials |
|
2.19
|
| Finished Goods |
|
0.48
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
1.33
|
| Other Current Assets |
|
0.31
|
| Total Non Current Assets |
|
26.47
|
| Net PPE |
|
12.40
|
| Gross PPE |
|
36.69
|
| Accumulated Depreciation |
|
-24.28
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.53
|
| Construction In Progress |
|
3.23
|
| Other Properties |
|
32.72
|
| Leases |
|
0.20
|
| Goodwill And Other Intangible Assets |
|
13.84
|
| Goodwill |
|
6.52
|
| Other Intangible Assets |
|
7.32
|
| Other Non Current Assets |
|
0.23
|
| Total Liabilities Net Minority Interest |
|
29.33
|
| Current Liabilities |
|
12.17
|
| Payables And Accrued Expenses |
|
7.97
|
| Payables |
|
7.66
|
| Accounts Payable |
|
3.34
|
| Current Accrued Expenses |
|
0.31
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.68
|
| Total Tax Payable |
|
4.32
|
| Current Debt And Capital Lease Obligation |
|
0.35
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.35
|
| Current Deferred Liabilities |
|
2.12
|
| Current Deferred Revenue |
|
2.12
|
| Other Current Liabilities |
|
0.05
|
| Total Non Current Liabilities Net Minority Interest |
|
17.15
|
| Long Term Debt And Capital Lease Obligation |
|
15.28
|
| Long Term Debt |
|
15.04
|
| Long Term Capital Lease Obligation |
|
0.24
|
| Non Current Deferred Liabilities |
|
0.19
|
| Non Current Deferred Revenue |
|
—
|
| Non Current Deferred Taxes Liabilities |
|
0.19
|
| Other Non Current Liabilities |
|
1.69
|
| Stockholders Equity |
|
12.69
|
| Common Stock Equity |
|
12.69
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
3.51
|
| Ordinary Shares Number |
|
3.51
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
250.74
|
| Retained Earnings |
|
-238.06
|
| Total Equity Gross Minority Interest |
|
12.69
|
| Total Capitalization |
|
27.73
|
| Working Capital |
|
3.37
|
| Invested Capital |
|
27.73
|
| Total Debt |
|
15.63
|
| Net Debt |
|
8.26
|
| Capital Lease Obligations |
|
0.59
|
| Net Tangible Assets |
|
-1.15
|
| Tangible Book Value |
|
-1.15
|
| Current Notes Payable |
|
—
|
| Current Provisions |
|
0.18
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.79
-1586.17%
|
0.19
+136.22%
|
-0.52
+43.83%
|
-0.92
|
| Cash Flow From Continuing Operating Activities |
|
-2.79
-1586.17%
|
0.19
+136.22%
|
-0.52
+43.83%
|
-0.92
|
| Net Income From Continuing Operations |
|
-6.26
+37.92%
|
-10.09
+6.87%
|
-10.83
-95.17%
|
-5.55
|
| Depreciation Amortization Depletion |
|
4.47
-15.83%
|
5.31
-10.08%
|
5.90
+3.76%
|
5.69
|
| Depreciation |
|
4.47
-15.83%
|
5.31
-10.08%
|
5.90
+3.76%
|
5.69
|
| Depreciation And Amortization |
|
4.47
-15.83%
|
5.31
-10.08%
|
5.90
+3.76%
|
5.69
|
| Other Non Cash Items |
|
-0.98
-760.81%
|
0.15
+5.71%
|
0.14
-10.83%
|
0.16
|
| Stock Based Compensation |
|
0.64
+50.59%
|
0.43
-67.23%
|
1.30
-11.12%
|
1.47
|
| Provisionand Write Offof Assets |
|
0.13
+170.88%
|
-0.18
-65.45%
|
-0.11
-202.80%
|
0.11
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
4.43
+93.96%
|
2.28
|
0.00
|
| Deferred Tax |
|
0.00
+100.00%
|
-0.19
-55.00%
|
-0.12
-400.00%
|
0.04
|
| Deferred Income Tax |
|
0.00
+100.00%
|
-0.19
-55.00%
|
-0.12
-400.00%
|
0.04
|
| Operating Gains Losses |
|
0.09
+87.76%
|
0.05
-95.01%
|
0.98
+1786.54%
|
0.05
|
| Gain Loss On Sale Of PPE |
|
0.09
+87.76%
|
0.05
-31.94%
|
0.07
+38.46%
|
0.05
|
| Change In Working Capital |
|
-0.89
-415.30%
|
0.28
+507.25%
|
-0.07
+97.61%
|
-2.88
|
| Change In Receivables |
|
1.00
+258.95%
|
-0.63
-547.52%
|
0.14
+112.31%
|
-1.15
|
| Changes In Account Receivables |
|
1.00
+258.95%
|
-0.63
-547.52%
|
0.14
+112.31%
|
-1.15
|
| Change In Inventory |
|
-0.29
-150.35%
|
0.57
-16.98%
|
0.69
+151.42%
|
-1.34
|
| Change In Prepaid Assets |
|
-0.25
-33.33%
|
-0.19
-176.83%
|
0.25
+321.62%
|
-0.11
|
| Change In Payables And Accrued Expense |
|
-0.90
-199.23%
|
0.91
+404.71%
|
-0.30
-135.70%
|
0.83
|
| Change In Accrued Expense |
|
-1.25
-167.13%
|
1.86
+1043.65%
|
-0.20
-186.03%
|
0.23
|
| Change In Payable |
|
0.35
+136.69%
|
-0.95
-854.00%
|
-0.10
-116.58%
|
0.60
|
| Change In Account Payable |
|
0.35
+136.69%
|
-0.95
-854.00%
|
-0.10
-116.58%
|
0.60
|
| Change In Other Working Capital |
|
-0.12
-115.79%
|
-0.06
+87.92%
|
-0.47
+26.71%
|
-0.64
|
| Change In Other Current Liabilities |
|
-0.33
-2.82%
|
-0.32
+15.16%
|
-0.38
+21.17%
|
-0.48
|
| Investing Cash Flow |
|
-1.47
+10.27%
|
-1.64
+67.40%
|
-5.02
-14.93%
|
-4.37
|
| Cash Flow From Continuing Investing Activities |
|
-1.47
+10.27%
|
-1.64
+67.40%
|
-5.02
-14.93%
|
-4.37
|
| Net PPE Purchase And Sale |
|
-1.47
+10.27%
|
-1.64
+67.40%
|
-5.02
-34.34%
|
-3.74
|
| Purchase Of PPE |
|
-1.47
+10.27%
|
-1.64
+67.40%
|
-5.02
-34.34%
|
-3.74
|
| Capital Expenditure |
|
-1.47
+10.27%
|
-1.64
+67.40%
|
-5.02
-34.34%
|
-3.74
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Business |
|
—
|
—
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-0.63
|
| Financing Cash Flow |
|
3.58
+85.92%
|
1.93
-71.94%
|
6.86
+1472.20%
|
-0.50
|
| Cash Flow From Continuing Financing Activities |
|
3.58
+85.92%
|
1.93
-71.94%
|
6.86
+1472.20%
|
-0.50
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
7.00
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
7.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
7.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
7.00
|
0.00
|
| Net Common Stock Issuance |
|
3.58
+84.20%
|
1.94
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
—
|
| Net Other Financing Charges |
|
—
|
-0.02
+87.05%
|
-0.14
+72.20%
|
-0.50
|
| Changes In Cash |
|
-0.68
-243.19%
|
0.48
-63.95%
|
1.32
+122.85%
|
-5.79
|
| Beginning Cash Position |
|
8.60
+5.88%
|
8.12
+19.47%
|
6.79
-46.01%
|
12.59
|
| End Cash Position |
|
7.91
-7.95%
|
8.60
+5.88%
|
8.12
+19.47%
|
6.79
|
| Free Cash Flow |
|
-4.26
-194.34%
|
-1.45
+73.85%
|
-5.54
-18.84%
|
-4.66
|
| Interest Paid Supplemental Data |
|
1.81
-8.21%
|
1.97
+39.43%
|
1.42
+90.19%
|
0.74
|
| Income Tax Paid Supplemental Data |
|
—
|
0.02
+4.55%
|
0.02
+15.79%
|
0.02
|
| Common Stock Issuance |
|
3.58
+84.20%
|
1.94
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
3.58
+84.20%
|
1.94
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-02-11 View
- 8-K2025-12-17 View
- 8-K2025-12-10 View
- 42025-11-18 View
- 10-Q2025-11-14 View
- 8-K2025-11-13 View
- 8-K2025-10-16 View
- 8-K2025-10-14 View
- 8-K2025-09-04 View
- 8-K2025-09-03 View
- 8-K2025-08-22 View
- 8-K2025-08-18 View
- 10-Q2025-08-14 View
- 8-K2025-08-13 View
- 8-K2025-08-07 View
- 8-K2025-05-19 View
- 42025-05-15 View
- 42025-05-15 View
- 42025-05-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|